NEW YORK (GenomeWeb News) — BioSeek said today that it has renewed and expanded an agreement to profile and guide optimization of lead compounds for the drug company UCB.
 
South San Francisco, Calif.-based BioSeek said it will profile selected chemical and biological entities and guide lead optimization of a specific phenotypic hit identified by UCB and characterized using the company’s BioMap screens.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.